Table 2.
TLR2/4 gene expression in murine sural nerves using RNAseq or microarray profiling
| Gene ID |
Gene Symbol |
Gene Description | db/+ vs db/db (8 wk (Hinder et al., 2018)) |
db/+ vs db/db (24 wk (Pande et al., 2011)) |
8wk vs 24 wk (db/db (Hinder et al., 2018)) |
Con vs Diabetic (26 wk (Wiggin et al., 2008)) |
db/+ vs db/db (16 wk (Hur et al., 2015)) |
db/db vs tx (16 wk (Hur et al., 2015)) |
ob/+ vs ob/ob (26 wk (O'Brien et al., 2016)) |
ob/+ vs ob/ob (5 wk (O'Brien et al., 2015)) |
5 wk vs 13 wk (ob/ob (O'Brien et al., 2015)) |
Con vs db/db (16 wk (Hinder et al., 2017b)) |
db/db vs tx (16 wk (Hinder et al., 2017b)) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11651 | Akt1 | thymoma viral proto-oncogene 1 | −1.18 | ||||||||||
| 11652 | Akt2 | thymoma viral proto-oncogene 2 | −1.38 | 1.7 | 1.22 | ||||||||
| 23797 | Akt3 | thymoma viral proto-oncogene 3 | −1.51 | −1.78 | −1.47 | −1.16 | |||||||
| 12370 | Casp8 | caspase 8 | 1.91 | 1.91 | 1.68 | ||||||||
| 20293 | Ccl12 | chemokine (C-C motif) ligand 12 | −1.78 | 2.59 | |||||||||
| 20302 | Ccl3 | chemokine (C-C motif) ligand 3 | 4.47 | −1.68 | 3.57 | −3.32 | 3.98 | ||||||
| 20303 | Ccl4 | chemokine (C-C motif) ligand 4 | 2.94 | 1.55 | −1.36 | ||||||||
| 20304 | Ccl5 | chemokine (C-C motif) ligand 5 | 3.2 | 4.12 | |||||||||
| 12475 | Cd14 | CD14 antigen | 1.46 | 2.26 | −1.54 | ||||||||
| 21939 | Cd40 | CD40 antigen | 1.6 | 2.09 | |||||||||
| 12524 | Cd86 | CD86 antigen | −1.69 | 1.36 | −1.65 | ||||||||
| 12675 | Chuk | conserved helix-loop-helix ubiquitous kinase | 1.2 | 1.34 | |||||||||
| 15945 | Cxcl10 | chemokine (C-X-C motif) ligand 10 | 7.2 | ||||||||||
| 17329 | Cxcl9 | chemokine (C-X-C motif) ligand 9 | 1.84 | −1.99 | 11.06 | ||||||||
| 14082 | Fadd | Fas (TNFRSF6)-associated via death domain | 1.85 | ||||||||||
| 15975 | Ifnar1 | interferon (alpha and beta) receptor 1 | −1.24 | −1.17 | |||||||||
| 15976 | Ifnar2 | interferon (alpha and beta) receptor 2 | 1.39 | ||||||||||
| 56489 | Ikbke | inhibitor of kappaB kinase epsilon | −1.31 | 1.61 | |||||||||
| 16151 | Ikbkg | inhibitor of kappaB kinase gamma | 1.43 | −1.23 | 1.16 | ||||||||
| 16176 | Il1b | interleukin 1 beta | 4.45 | −4.62 | |||||||||
| 54131 | Irf3 | interferon regulatory factor 3 | −1.39 | ||||||||||
| 27056 | Irf5 | interferon regulatory factor 5 | 1.7 | 1.46 | 2.39 | ||||||||
| 54123 | Irf7 | interferon regulatory factor 7 | −2.24 | 2.07 | −1.69 | ||||||||
| 16476 | Jun | Jun oncogene | −1.44 | ||||||||||
| 16803 | Lbp | lipopolysaccharide binding protein | 1.73 | 1.81 | −1.38 | 1.48 | −1.27 | 1.44 | |||||
| 17087 | Ly96 | lymphocyte antigen 96 | 1.37 | ||||||||||
| 26395 | Map2k1 | mitogen-activated protein kinase kinase 1 | 1.27 | ||||||||||
| 26397 | Map2k3 | mitogen-activated protein kinase kinase 3 | 1.46 | 1.33 | |||||||||
| 26398 | Map2k4 | mitogen-activated protein kinase kinase 4 | 1.19 | ||||||||||
| 26399 | Map2k6 | mitogen-activated protein kinase kinase 6 | −1.32 | ||||||||||
| 26400 | Map2k7 | mitogen-activated protein kinase kinase 7 | −1.24 | 1.3 | |||||||||
| 26410 | Map3k8 | mitogen-activated protein kinase kinase kinase 8 | 1.5 | 1.63 | |||||||||
| 26413 | Mapk1 | mitogen-activated protein kinase 1 | −1.28 | ||||||||||
| 26414 | Mapk10 | mitogen-activated protein kinase 10 | −15.96 | −1.76 | |||||||||
| 29857 | Mapk12 | mitogen-activated protein kinase 12 | −1.58 | −1.51 | 1.55 | ||||||||
| 26417 | Mapk3 | mitogen-activated protein kinase 3 | −1.24 | ||||||||||
| 26420 | Mapk9 | mitogen-activated protein kinase 9 | 1.18 | ||||||||||
| 18035 | Nfkbia | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | −1.48 | 1.28 | |||||||||
| 18706 | Pik3ca | phosphatidylinositol 3-kinase, catalytic, alpha polypeptide | 1.23 | ||||||||||
| 74769 | Pik3cb | phosphatidylinositol 3-kinase, catalytic, beta polypeptide | 1.89 | 1.73 | 1.77 | 1.38 | |||||||
| 18709 | Pik3r2 | phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) | −1.53 | −1.44 | −1.47 | ||||||||
| 18710 | Pik3r3 | phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) | 1.43 | 1.47 | 1.3 | ||||||||
| 320207 | Pik3r5 | phosphoinositide-3-kinase, regulatory subunit 5, p101 | 1.78 | 3.05 | 1.98 | 2.62 | 1.87 | 4.32 | |||||
| 19697 | Rela | v-rel reticuloendotheliosis viral oncogene homolog A (avian) | −1.15 | ||||||||||
| 19766 | Ripk1 | receptor (TNFRSF)-interacting serine-threonine kinase 1 | 1.36 | ||||||||||
| 20750 | Spp1 | secreted phosphoprotein 1 | −1.32 | −1.26 | 1.53 | −2.13 | |||||||
| 20846 | Stat1 | signal transducer and activator of transcription 1 | −1.35 | ||||||||||
| 66513 | Tab1 | TGF-beta activated kinase 1/MAP3K7 binding protein 1 | −1.3 | −1.28 | 1.26 | −1.23 | |||||||
| 68652 | Tab2 | TGF-beta activated kinase 1/MAP3K7 binding protein 2 | −1.27 | ||||||||||
| 56480 | Tbk1 | TANK-binding kinase 1 | 1.27 | 1.23 | 1.28 | ||||||||
| 106759 | Ticam1 | toll-like receptor adaptor molecule 1 | −1.28 | ||||||||||
| 24088 | Tlr2 | toll-like receptor 2 | 1.34 | −1.52 | |||||||||
| 21926 | Tnf | tumor necrosis factor | 2.06 | 1.47 | |||||||||
| 54473 | Tollip | toll interacting protein | 1.12 | ||||||||||
| 22031 | Traf3 | TNF receptor-associated factor 3 | 1.45 |
Previously published data (Hinder et al., 2017b; Hur et al., 2015; O'Brien et al., 2015; O'Brien et al., 2016; Pande et al., 2011; Wiggin et al., 2008) represented as relative fold changes in sural nerve gene expression across murine models of neuropathy. Con=control and tx=treated. The group listed first is the group used as reference.